Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 477-479

  Grande, Enrique ^a   Díez, Juan José ^a   Pachón, Vanessa ^a   Vaz, María Ángeles ^a   Longo, Federico ^a   Guillén, Carmen ^a   De Paredes, María Luisa García ^a   Carrato, Alfredo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Choi criteria; octreotide long acting release; pancreatic neuroendocrine tumors; sunitinib

Indexed keywords

CISPLATIN; ETOPOSIDE; OCTREOTIDE; SUNITINIB;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MEDICAL HISTORY; NEUROENDOCRINE TUMOR; PANCREAS BIOPSY; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; ULTRASOUND;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PYRROLES;

EID: 79955052620     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328344484b     Document Type: Article

References (9)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after acarcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26:3063-3072.
2. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35. (Pubitemid 46630490)
3. Raymond E, Niccoli-Sire P, Bang Y, Borbath I, Lombard-Bohas C, Valle JW, et al. Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). Presented at the 2010 Gastrointestinal Cancers Symposium, Abstract 127.
4. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
5. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759. (Pubitemid 46797957)
6. Clark OH, Benson AB III, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. NCCN Neuroendocrine Tumors Panel Members. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009; 7:712-747.
7. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102:803-809.
8. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010; 194:157-165.
9. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; 9:20-22.